Tetra Bio-Pharma Inc (TSE:TBP) (OTCQB:TBPMF) CEO Guy Chamberland tells Proactive the FDA has cleared its investigational new drug application on its cancer painkiller QIXLEEF. The approval means that the Ottawa-based company can now start a 10-week clinical trial in cancer patients with breakthrough pain.
In addition, Chamberland says the company has created a wholly-owned subsidiary called ENJOUCA. Jurisdictions differ greatly in terms of regulatory requirements surrounding medical cannabis, which means that in some territories, QIXLEEF can be commercialized as a medical cannabis product.